Dr. Cheng Zhang
Dr. Cheng Zhang
Mercy Health, USA
Title: The Current Treatment of Ulcerative Colitis in the USA
Ulcerative colitis (UC) is a chronic disease characterized by diffuse mucosal inflammation limited to the colon. UC affects approximately 500,000 individuals in the US with an incidence of 8 – 12 per 100,000 population per year. UC accounts for 1/4 million physician visits annually, 30,000 hospitalizations, and loss of over 1 million workdays per year. The direct medical costs alone exceed 4 billion dollars annually. Although some UC patient might eventually need surgery for medically refractory disease, chronic corticosteroids use, dysplasia, or colorectal cancer, many UC patients are still able to achieve clinical remission and mucosal healing with current available medical treatments. This review will focus on current available medicines that are used in the United States of America (USA) to treat UC. It will discuss corticosteroids, mesalamine, thiopurines, calcineurin inhibitors, anti- tumor necrosis factor (TNF) monoclonal antibodies, anti-α4β7 integrins monoclonal antibodies, Janus kinases inhibitor, and biosimilars. The review will discuss the current algorithm of medically treating UC in the USA. It will also provide evidence of using these medicines in treating UC based on the most recent clinical trials. At the last, the review will also compare the difference of medical treatments between Crohn’s disease and UC.
Dr. Cheng Zhang graduated from Xinagya School of Medicine, Central South University, China in 1995 with MD degree. Afterwards, he had completed Otolaryngology resident and fellowship training in Beijing Hospital in China. In 2005, he obtained Ph.D degree in the field of Molecular Biology at the School of Pharmacy, University of Southern California in Los Angeles, USA. Then he started medicine residency training in the Greater Baltimore Medical Center, affiliated to the Johns Hopkins University at Baltimore, MD USA. In 2009 after he completed the medicine residency training, he started gastroenterology fellowship training in Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA USA. After his one-year tenure as a gastroenterology consultant in the CoxHealth in Springfield Missouri from 2012 to 2013, he joined the Ohio State University as an assistant professor. From 2013 to 2018, at the Ohio State University, he had led multiple multi-center clinical trials and studies regarding inflammatory bowel disease. He also received multiple institutional and national awards of outcome research about gastrointestinal diseases. He has received many grants to support this research. He has published multiple research papers in highly regarded journals as either a first author or a senior author. He currently is a director of gastroenterology program in MercyCrest Gastroenterology at the Springfield Regional Medical Center, Mercy Health. His clinical interests are Inflammatory bowel disease, gastrointestinal bleeding, and chronic diarrhea. His research interests are translational and outcome clinical research in gastrointestinal disease, particularly inflammatory bowel disease. He is also interested quality improvement in gastrointestinal diseases.